Role of new serological markers in evaluating the progression of liver disease in patients with chronic HBV infection and normal aminotransferases
10.3969/j.issn.1001-5256.2023.03.026
- VernacularTitle:新型血清学指标在评估转氨酶正常的慢性HBV感染者肝病进展中的作用
- Author:
Yuan WANG
1
;
Huaie LIU
1
;
Jie DING
2
;
Qingqing WANG
2
;
Aili WANG
1
;
Hui SUN
1
;
Hui CAO
1
Author Information
1. Department of Infectious Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
2. Department of Hepatology, The Third People's Hospital of Kunming, Kunming 650032, China
- Publication Type:Review
- Keywords:
Hepatitis B, Chronic;
Serology;
Transaminase
- From:
Journal of Clinical Hepatology
2023;39(3):644-650
- CountryChina
- Language:Chinese
-
Abstract:
Antiviral therapy is the basic treatment method for improving prognosis recommended in the management guidelines of chronic hepatitis B in China and globally. For patients with chronic HBV infection and normal transaminases, it is difficult in clinical practice to accurately evaluate the progression of hepatitis and identify suitable patients who need antiviral therapy. In order to objectively and accurately evaluate the degree of liver inflammatory activity in such patients, more and more noninvasive evaluation indicators have been used in addition to conventional liver biopsy. This article reviews the new serological indicators that can reflect the degree of liver inflammation and/or fibrosis in patients with chronic HBV infection and normal aminotransferase levels, hoping to provide a reference for antiviral decision-making in these patients.
